ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AtriCure Inc (ATRC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is facing competitive pressures, insider selling, and a bearish technical trend. While the company has shown revenue growth, profitability metrics have significantly declined, and analyst sentiment is mixed with recent downgrades. It would be prudent to monitor the stock for further developments before committing to an investment.
The technical indicators suggest a bearish trend. The MACD is negative and expanding downward, the RSI is neutral but leaning towards oversold territory, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a key support level at 29.972, with resistance at 31.474.
The company has shown revenue growth of 13.05% YoY in Q4 2025 and maintains a strong gross margin of 74.97%. Analysts from Canaccord, UBS, and Citizens remain optimistic about the company's competitive moat and long-term growth potential.
Significant insider selling (521.10% increase last month), competitive threats from Edwards Lifesciences and Medtronic, and recent analyst downgrades from Oppenheimer and JPMorgan. Additionally, the stock is expected to decline further in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased by 13.05% YoY to $140.5 million. However, net income dropped by -111.28% YoY to $1.756 million, and EPS fell by -112.12% YoY to $0.04. Gross margin improved slightly to 74.97%.
Analyst sentiment is mixed. Recent downgrades include Oppenheimer (to Perform from Outperform) and JPMorgan (to Neutral from Overweight). Price targets have been lowered across the board, with Canaccord, UBS, and Citizens maintaining Buy or Outperform ratings but reducing price targets to $53, $55, and $52, respectively.
